Executive Summary — Typhoid Vaccine Market

Typhoid vaccine market size was valued at USD 434.93 million in 2024 and is projected to reach USD 973.78 million by 2032, with a CAGR of 10.60% during the forecast period of 2025 to 2032.

In this Typhoid Vaccine Market report, industry trends are analyzed at a macro level to help stakeholders understand the market landscape and emerging challenges. This market report is the product of continuing efforts by experienced forecasters, analysts, and researchers who engage in careful research on market dynamics, trends, and opportunities. Estimates related to CAGR for the forecast period, market drivers, restraints, and competitive strategies are evaluated in the report. The research helps businesses make informed strategic decisions and plan successful market actions.

The report explores market breakdowns by manufacturers, region, vaccine type, distribution channels, application, market status, market share, growth rate, future trends, opportunities and challenges, regulatory landscape, sales channels, and distribution networks. It also provides granular analysis of market share, segmentation, revenue forecasts, and regional performance to guide growth strategy. The Typhoid Vaccine Market report delivers up-to-date industry data and forward-looking trends to identify products and end-users driving revenue growth and profitability.

Discover the latest trends, growth opportunities, and strategic insights in our comprehensive Typhoid Vaccine Market report. Download Full Report: https://www.databridgemarketresearch.com/reports/global-typhoid-vaccine-market

Typhoid Vaccine Market Overview

Segments

• By Vaccine Type: Typhoid Conjugate Vaccines (TCV), Vi Capsular Polysaccharide (Vi-PS) Vaccines, Live Attenuated (Ty21a)
• By Presentation: Single Dose, Multi Dose, Oral Capsules
• By Route of Administration: Intramuscular, Oral
• By End-User: Hospitals, Government Immunization Programs, Private Clinics, Travel Clinics
• By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

The global Typhoid Vaccine market is segmented by vaccine type, presentation, administration route, end-user, and region. Typhoid conjugate vaccines (TCVs) are gaining traction because they can be administered to younger children and confer longer-lasting protection. Vi polysaccharide vaccines and oral Ty21a vaccines continue to be used in specific settings, including travel medicine and outbreak control. Mass immunization programs and inclusion in national immunization schedules are key factors driving demand in endemic regions.

Market Players

• Bharat Biotech International Ltd. (Typbar-TCV)
• Sanofi Pasteur (TYPHIM Vi)
• Biological E. Limited (TYPHIBEV)
• GlaxoSmithKline (Typherix — historical Vi-PS)
• SK bioscience (SKYTyphoid™)
• Zydus Lifesciences (ZyVac® TCV)
• Emergent BioSolutions / PaxVax (Vivotif® — oral Ty21a)
• Serum Institute / regional vaccine manufacturers
• Public health procurement agencies and Gavi-supported suppliers
• Others

Key players in the Typhoid Vaccine market include global vaccine manufacturers, specialty biologics firms, and regional producers. Companies are pursuing product development (including conjugate vaccine platforms), WHO prequalification, capacity expansion, partnerships with global health bodies, and inclusion in national immunization programs to expand reach in endemic countries.

Market Dynamics & Trends

The Typhoid Vaccine market is experiencing robust growth driven by rising public health initiatives, expanding National Immunization Program (NIP) adoption of typhoid conjugate vaccines, and increased funding from international organizations to control enteric fever in endemic regions. Improvements in cold-chain logistics, greater awareness, and stronger surveillance systems are supporting vaccine uptake.

A major trend is the shift toward typhoid conjugate vaccines (TCVs). TCVs are suitable for infants and children, offer longer duration of protection, and fit well into routine immunization schedules — making them central to sustained disease control strategies. Additionally, manufacturers are investing in local production and WHO prequalification to supply low- and middle-income countries at scale.

Other key dynamics include enhanced public–private partnerships for vaccine delivery, emphasis on vaccine affordability and access, and ongoing R&D for improved formulations and thermostable presentations. Surveillance-driven, targeted campaigns and school-based vaccination drives are also important demand drivers.

Regional Outlook

Asia-Pacific (notably South Asia) and parts of Africa account for a substantial portion of demand due to higher typhoid incidence. Routine immunization campaigns and Gavi-supported introductions have accelerated adoption in these regions. Meanwhile, travel medicine and outbreak response sustain demand in North America and Europe.

Key Growth Drivers

• Increased inclusion of TCVs in national immunization schedules.
• WHO prequalification and Gavi funding enabling widescale procurement.
• Rising public health focus on antimicrobial resistance and prevention.
• Improved surveillance and diagnostics enabling targeted vaccination campaigns.

Challenges & Restraints

• Cold-chain and distribution challenges in remote areas.
• Affordability and procurement constraints for some governments.
• Vaccine hesitancy and gaps in community outreach in certain geographies.
• Ongoing need for safety monitoring and post-introduction effectiveness data.

Typhoid Vaccine Market Research Questions

• How much has the Typhoid Vaccine Market grown year over year?
• What is the future market-size forecast for the global Typhoid Vaccine Market?
• Which vaccine types (TCV, Vi-PS, Ty21a) dominate by revenue and uptake?
• Which manufacturers hold the most competitive advantage in supply and WHO prequalification?
• Which regions are prioritized for vaccine introduction and scale-up?
• How are funding mechanisms (Gavi, UNICEF, national budgets) shaping procurement?

DBMR Nucleus: Powering Insights, Strategy & Growth

DBMR Nucleus is an AI-powered business intelligence platform that delivers real-time market data, competitive landscape analysis, and growth opportunity signals. It supports strategic decisions across the vaccine value chain — from forecasting demand and identifying supply gaps to planning capacity expansions and pricing strategies.

Reasons to Consider This Report

• Understand the Typhoid Vaccine landscape and identify high-return segments.
• Keep pace with changes in competitive positioning and regulatory approvals.
• Plan M&A and partnership strategies by identifying markets with strong procurement potential.
• Obtain market revenue forecasts by vaccine type and region to inform manufacturing investments.
• Get evidence required for policy advocacy, funding proposals, and program planning.

Inspect market share figures by company

https://www.databridgemarketresearch.com/reports/global-typhoid-vaccine-market/companies

Browse More Reports

Global Ameloblastic carcinoma Market
Global Aminosalicylates Market
Global Amniotic Band Syndrome Market
Global Anaesthesia and Respiratory Devices Market
Global Anal Fistula Treatment Market
Global Analytics-as-a-Service (AaaS) Market
Global Anca Vasculitis Treatment Market
Global Angiofibroma Drugs Market
Global Animal Disinfectants Market
Global Animal Product Residue Monitoring Market
Global Animal Treatment Market
Global Antibacterial Market
Global Anti-CD19 Therapeutic Antibody Market
Global Anticoagulants Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today! Data Bridge Market Research is a market research and consulting firm focused on delivering actionable insights to help organizations identify market opportunities and make strategic decisions. Founded in 2015 in Pune, DBMR blends experienced analysts with modern intelligence tools to serve clients worldwide.

Contact Us:

Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC: +65 3125 1975
Email: corporatesales@databridgemarketresearch.com